© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Apr 18, 2014, the consensus forecast amongst 32 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 24 analysts offering 12 month price targets for
Dividend information is not available for
On Apr 22, 2014,
|Average growth rate||+45.76%|
|Average growth rate||+10.28%|
Gilead Sciences Inc. had 1st quarter 2014 revenues of 5.00bn. This bettered the 3.98bn consensus of the 21 analysts covering the company. This was 60.23% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+20.55%|
Gilead Sciences Inc. had revenues for the full year 2013 of 11.20bn. This was 15.45% above the prior year's results. View Full Annual Financials
|Average growth rate||+12.51%|